Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.

A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.

Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, Jin Y, Yu L, Grainger DW, Ying W.

Int J Med Sci. 2014 Mar 18;11(5):479-87. doi: 10.7150/ijms.8340. eCollection 2014.

2.

Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics.

Hapuarachchige S, Zhu W, Kato Y, Artemov D.

Biomaterials. 2014 Feb;35(7):2346-54. doi: 10.1016/j.biomaterials.2013.11.075. Epub 2013 Dec 15.

3.

Nanotechnologies for noninvasive measurement of drug release.

Moore T, Chen H, Morrison R, Wang F, Anker JN, Alexis F.

Mol Pharm. 2014 Jan 6;11(1):24-39. doi: 10.1021/mp400419k. Epub 2013 Nov 26. Review.

4.

Clinically relevant anticancer polymer Paclitaxel therapeutics.

Yang D, Yu L, Van S.

Cancers (Basel). 2010 Dec 23;3(1):17-42. doi: 10.3390/cancers3010017.

5.

Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.

Ernsting MJ, Murakami M, Roy A, Li SD.

J Control Release. 2013 Dec 28;172(3):782-94. doi: 10.1016/j.jconrel.2013.09.013. Epub 2013 Sep 25. Review.

6.

Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC.

Chem Soc Rev. 2012 Apr 7;41(7):2971-3010. doi: 10.1039/c2cs15344k. Epub 2012 Mar 5. Review.

7.

Nanoparticle PEGylation for imaging and therapy.

Jokerst JV, Lobovkina T, Zare RN, Gambhir SS.

Nanomedicine (Lond). 2011 Jun;6(4):715-28. doi: 10.2217/nnm.11.19. Review.

8.

Procoagulant inhibitory properties of paclitaxel poliglumex.

Nemunaitis J, Senzer N, Cooper B, Nemunaitis M, Bedell C, Singer JW, Oldham FB.

Int J Gen Med. 2010 Dec 15;4:5-11. doi: 10.2147/IJGM.S12170.

9.

Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate.

Van S, Das SK, Wang X, Feng Z, Jin Y, Hou Z, Chen F, Pham A, Jiang N, Howell SB, Yu L.

Int J Nanomedicine. 2010 Oct 21;5:825-37. doi: 10.2147/IJN.S13482.

10.

Small-molecule delivery by nanoparticles for anticancer therapy.

Chen ZG.

Trends Mol Med. 2010 Dec;16(12):594-602. doi: 10.1016/j.molmed.2010.08.001. Epub 2010 Sep 16. Review.

11.

Targeted cytosolic delivery of cell-impermeable compounds by nanoparticle-mediated, light-triggered endosome disruption.

Febvay S, Marini DM, Belcher AM, Clapham DE.

Nano Lett. 2010 Jun 9;10(6):2211-9. doi: 10.1021/nl101157z.

12.

Advances of cancer therapy by nanotechnology.

Wang X, Wang Y, Chen ZG, Shin DM.

Cancer Res Treat. 2009 Mar;41(1):1-11. doi: 10.4143/crt.2009.41.1.1. Epub 2009 Mar 31.

13.

In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

Bisht S, Feldmann G, Koorstra JB, Mullendore M, Alvarez H, Karikari C, Rudek MA, Lee CK, Maitra A, Maitra A.

Mol Cancer Ther. 2008 Dec;7(12):3878-88. doi: 10.1158/1535-7163.MCT-08-0476.

14.

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Alexis F, Pridgen E, Molnar LK, Farokhzad OC.

Mol Pharm. 2008 Jul-Aug;5(4):505-15. doi: 10.1021/mp800051m. Epub 2008 Aug 4. Review.

15.

Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.

Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Sep;110(3):329-35. doi: 10.1016/j.ygyno.2008.05.008. Epub 2008 Jul 1.

16.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer.

Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P.

Br J Cancer. 2008 May 20;98(10):1608-13. doi: 10.1038/sj.bjc.6604372. Epub 2008 May 13.

17.

Polymer-drug conjugates: recent development in clinical oncology.

Li C, Wallace S.

Adv Drug Deliv Rev. 2008 May 22;60(8):886-98. doi: 10.1016/j.addr.2007.11.009. Epub 2008 Feb 8. Review.

18.

Nanotechnology and cancer.

Heath JR, Davis ME.

Annu Rev Med. 2008;59:251-65. Review.

19.

Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts.

Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J.

Neoplasia. 2007 Jun;9(6):479-86.

20.

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation.

Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y.

Br J Cancer. 2007 Jul 16;97(2):170-6. Epub 2007 Jun 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk